DR. LEE ERIC TANNENBAUM M.D.
Prescription History 1528030004
Family Medicine - Addiction Medicine in Bel Air, MD

NPI Status: Active since February 07, 2006

Contact Information

2012 S TOLLGATE RD
STE 106
BEL AIR, MD
ZIP 21015
Phone: (410) 569-9429
Fax: (410) 569-9423

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. LEE ERIC TANNENBAUM M.D., an active Addiction Medicine specialist practicing in Bel Air, MD. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 108 documented patient claims. Among these therapy options, the most frequently utilized medication is Buprenorphine-Naloxone, which accounts for 43 claims alone.

Medication Index


Buprenorphine-Naloxone

Generic Formulation: Buprenorphine Hcl/Naloxone HclSpecialty: Family Medicine
Provider Metrics Summary
Total Claims 43
30-Day Fills 44.0
Days Supply 1,297
MD State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills53.3
Peer Average Days Supply1,151
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,689.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$225.33

State Avg Cost Per Claim

$224.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: buprenorphine and naloxone. It is used to treat opioid dependence/addiction. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. Buprenorphine helps prevent withdrawal symptoms caused by stopping other opioids. Naloxone is an opioid antagonist that blocks the effect of opioids and can cause severe opioid withdrawal when injected. It has little effect when taken by mouth or dissolved under the tongue. It is combined with buprenorphine to prevent abuse and misuse (injection) of this medication. This combination medication is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). Ask your doctor or pharmacist if you should have other forms of naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it.

Diazepam

Generic Formulation: DiazepamSpecialty: Family Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
MD State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills26.4
Peer Average Days Supply647
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.2% less volume than the regional standard for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $75.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.87

State Avg Cost Per Claim

$8.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.

Therapeutic Applications

This medication is used to treat episodes of increased seizures (such as cluster or breakthrough seizures) in people who are already taking medications to control their seizures. This product is only recommended for short-term treatment of seizure attacks. It is not for ongoing daily use to prevent seizures. Uncontrolled seizures can turn into serious (possibly fatal) seizures that do not stop (status epilepticus). This medication is not recommended for children younger than 6 months of age because of the risk of serious side effects. Diazepam works by calming the brain and nerves. It belongs to a class of drugs known as benzodiazepines.

Methadone Hcl

Generic Formulation: Methadone HclSpecialty: Family Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
MD State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills37.9
Peer Average Days Supply1,030
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.6% less volume than the regional standard for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $792.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$66.00

State Avg Cost Per Claim

$19.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)

Therapeutic Applications

This medication is used to treat addiction to opioids (such as heroin) as part of an approved treatment program. Methadone belongs to a class of drugs known as opioid analgesics. It helps prevent withdrawal symptoms caused by stopping other opioids.

Zolpidem Tartrate

Generic Formulation: Zolpidem TartrateSpecialty: Family Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
MD State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills46.9
Peer Average Days Supply1,380
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.7% less volume than the regional standard for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $165.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.79

State Avg Cost Per Claim

$10.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.

Therapeutic Applications

Zolpidem is used for a short time to treat a certain sleep problem (insomnia) in adults. If you have trouble falling asleep, it helps you fall asleep faster, so you can get a better night's rest. Zolpidem belongs to a class of drugs called sedative-hypnotics. It acts on your brain to produce a calming effect.

Zolpidem Tartrate Er

Generic Formulation: Zolpidem TartrateSpecialty: Family Medicine
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 537
MD State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills19.6
Peer Average Days Supply580
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $787.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.78

State Avg Cost Per Claim

$49.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.

Therapeutic Applications

Zolpidem is used for a short time to treat a certain sleep problem (insomnia) in adults. If you have trouble falling asleep, it helps you fall asleep faster, so you can get a better night's rest. Zolpidem belongs to a class of drugs called sedative-hypnotics. It acts on your brain to produce a calming effect.

Zubsolv

Generic Formulation: Buprenorphine Hcl/Naloxone HclSpecialty: Family Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.7
Days Supply 374
MD State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.5
Peer Average Days Supply444
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,046.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$420.54

State Avg Cost Per Claim

$509.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: buprenorphine and naloxone. It is used to treat opioid dependence/addiction. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. Buprenorphine helps prevent withdrawal symptoms caused by stopping other opioids. Naloxone is an opioid antagonist that blocks the effect of opioids and can cause severe opioid withdrawal when injected. It has little effect when taken by mouth or dissolved under the tongue. It is combined with buprenorphine to prevent abuse and misuse (injection) of this medication. This combination medication is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). Ask your doctor or pharmacist if you should have other forms of naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. LEE ERIC TANNENBAUM M.D. provides transparency into local medical care patterns within Bel Air, MD.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Addiction Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.